We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
- Authors
Zhang, W.; McQueen, T.; Schober, W.; Rassidakis, G.; Andreeff, M.; Konopleva, M.
- Abstract
Anaplastic large-cell lymphoma (ALCL) is a heterogeneous lymphoma category in which a subset of cases carry the t(2;5)(p23;q35) or variant translocations resulting in overexpression of anaplastic lymphoma kinase (ALK). LY293111 (2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]-phenoxy] benzoic acid sodium salt) is a leukotriene B4 receptor antagonist, which was found to be safe and tolerable in Phase I clinical trials. In this study, we investigated the potential therapeutic effects and mechanisms of action of LY293111 in ALCL cell lines. LY293111 inhibited proliferation of both ALK(+) and ALK(−) ALCL cell in a dose-dependent fashion and induced complete G1–S cell cycle arrest, which was accompanied by upregulation of p27 and downregulation of cyclin E. Pretreatment with LY293111 for 4 h resulted in profound inhibition of serum-induced phosphorylation of extracellular-regulated kinases-1 and 2 and Akt and a concomitant increase in the phosphorylation of the stress-activated kinase c-jun N-terminal kinases (JNK). Simultaneously, LY293111 induced caspase-dependent apoptosis via activation of the intrinsic pathway, including early loss of mitochondrial inner transmembrane potential and the production of reactive oxygen species (ROS), cleavage of caspases-9, -3, poly ADP-ribose polymerase (PARP) and X-linked inhibitor of apoptosis. The phospho-JNK inhibitor SP600125 partially protected Sup-M2 cells from LY293111-induced apoptosis, PARP cleavage and ROS generation, suggesting a role for JNK in LY293111-induced cell death. These results warrant further studies of LY293111 in ALCL.Leukemia (2005) 19, 1977–1984. doi:10.1038/sj.leu.2403929; published online 8 September 2005
- Subjects
LYMPHOMAS; LEUKOTRIENE antagonists; CLINICAL trials; THERAPEUTICS; CELL proliferation; CELL cycle; PHOSPHORYLATION
- Publication
Leukemia (08876924), 2005, Vol 19, Issue 11, p1977
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/sj.leu.2403929